Search
SOLACI Congress
HomeCONGRESS

CONGRESS

View Category
Day 3

TRANSLATE-ACS: One-year prasugrel versus clopidogrel after acute coronary syndrome

Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute...
solaci -
Learn More
Day 3

ISAR-TRIPLE: 6 weeks versus 6 months of clopidogrel in patients with oral anticoagulation and drug-eluting stent

There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination...
solaci -
Learn More
Day 3

BRIGHT: Bivalirudin versus heparin versus heparin plus tirofiban in primary angioplasty

The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB...
solaci -
Learn More
Day 1

ISAR-CLOSURE: FemoSeal and ExoSeal versus manual compression after femoral access

Previous studies with vascular closure devices showed shorter hemostasis and less downtime post-procedure. This study compared the...
solaci -
Learn More
Day 1

CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection

The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times...
solaci -
Learn More
Day 1

PARTNER cohort B: 5-year results of a balloon-expandable valve on inoperable patients

This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment....
solaci -
Learn More
Day 1

CoreValve US Pivotal Trial: 2-year results of the self-expanding valve on inoperable patients

This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe...
solaci -
Learn More
Day 1

US CoreValve: Cost effectiveness of transcatheter replacement versus surgical replacement in high-risk patients

Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dr. Juan Manuel Pérez - 0
Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

Dr. Omar Tupayachi - 0
The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

How real are the adverse effects of statins? Evidence from randomized clinical trials

Dr. Juan Manuel Pérez - 0
The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Institutional News

Fellow’s Corner 2026 – Submit Your Clinical Case

solaci - 0
Share your experience. Learn from experts. Grow as an interventional cardiologist. The Latin American Society of Interventional Cardiology (SOLACI) is relaunching this year the Fellow’s...

Watch Again: Cardiovascular Risk Factors in Women | SOLACI Technicians Webinar

solaci - 0
The webinar “Cardiovascular Risk Factors in Women,” held on January 27, 2026, via the Zoom platform, is now available for viewing on SOLACI’s YouTube...

Technical Training in Hemodynamics and Interventional Cardioangiology | SOLACI–CACI

solaci - 0
The SOLACI–CACI Technical Training in Hemodynamics and Interventional Cardioangiology is an academic program designed for the initial training and professional development of non-physician healthcare...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy